Catalyst Pharma Files Q2 2025 10-Q
Ticker: CPRX · Form: 10-Q · Filed: 2025-08-06T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, revenue, pharmaceuticals
Related Tickers: CPRX
TL;DR
CPRX Q2 2025 10-Q filed. Revenue details, assets, and stock info updated.
AI Summary
Catalyst Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The company reported sales revenue net for Customer A and provided details on its financial position, including U.S. Treasury Securities and intangible assets related to RUZURGI. The filing also references restricted stock units and additional paid-in capital.
Why It Matters
This filing provides investors with an update on Catalyst Pharmaceuticals' financial performance and position for the second quarter of 2025, including key revenue and asset details.
Risk Assessment
Risk Level: medium — The filing contains financial data and operational updates typical for a pharmaceutical company, which inherently carries risks related to drug development, market approval, and sales.
Key Numbers
- 2025-06-30 — Reporting Date (End of the fiscal period covered by the 10-Q.)
- 2025-04-01 — Start of Reporting Period (Beginning of the fiscal quarter for which the report is filed.)
- 2024-06-30 — Prior Year Quarter End (For comparative financial analysis.)
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Filer
- 20250630 (date) — Period of Report
- 355 ALHAMBRA CIRCLE (address) — Business Address
- RUZURGI (drug) — Acquired Intangibles
- Customer A (company) — Sales Revenue Source
FAQ
What was the net sales revenue from Customer A for the period ending June 30, 2025?
The filing indicates sales revenue net for Customer A, but the specific dollar amount is not provided in the excerpt.
What is the nature of the intangible assets related to RUZURGI mentioned in the filing?
The filing refers to 'LicenseAndAcquiredIntangiblesForRUZURGIMember', suggesting these are intellectual property or rights associated with the drug RUZURGI.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
What type of securities does Catalyst Pharmaceuticals hold as U.S. Treasury Securities?
The filing mentions 'us-gaap:USTreasurySecuritiesMember' for both June 30, 2025, and December 31, 2024, indicating holdings in U.S. Treasury Securities.
When was Catalyst Pharmaceuticals, Inc. formerly known as Catalyst Pharmaceutical Partners, Inc.?
The company changed its name from Catalyst Pharmaceutical Partners, Inc. on February 15, 2011.
From the Filing
0000950170-25-104000.txt : 20250806 0000950170-25-104000.hdr.sgml : 20250806 20250806160825 ACCESSION NUMBER: 0000950170-25-104000 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 251189573 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 10-Q 1 cprx-20250630.htm 10-Q 10-Q false Q2 --12-31 0001369568 3 5 5 http://catalystpharma.com/20250630#PresidentAndChiefExecutiveOfficerMember 6 years http://fasb.org/us-gaap/2025#LiabilitiesCurrent http://fasb.org/us-gaap/2025#LiabilitiesCurrent 0001369568 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001369568 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001369568 us-gaap:USTreasurySecuritiesMember 2025-06-30 0001369568 cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember 2025-04-01 2025-06-30 0001369568 cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember cprx:AgamreeMember 2025-01-01 2025-06-30 0001369568 2024-04-01 2024-06-30 0001369568 2023-12-31 0001369568 us-gaap:USTreasurySecuritiesMember 2024-12-31 0001369568 cprx:AgamreeMember 2023-10-01 2023-12-31 0001369568 us-gaap:SalesRevenueNetMember cprx:CustomerAMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0001369568 cprx:ProductRevenueNetMember 2025-04-01 2025-06-30 0001369568 cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember srt:MinimumMember cprx:AgamreeMember 2025-01-01 2025-06-30 0001369568 cprx:AgamreeMember cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember 2025-01-01 2025-06-30 0001369568 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-06-30 0001369568 cprx:LicensedAndAcquiredIntangiblesForAgamreeMember 2025-06-30 0001369568 srt:MinimumMember cprx:AgamreeMember cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember 2025-01-01 2025-06-30 0001369568 srt:MinimumMember cprx:LicenseAgreementWithBioMarinMember 2025-01-01 2025-06-30 0001369568 us-gaap:ResearchAndDevelopmentExpenseMember 2025-04-01 2025-06-30 0001369568 2024-01-01 2024-12-31 0001369568 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001369568 us-gaap:CommonStockMember 2025-06-30 0001369568 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001369568 us-gaap:CommonStockMember 2024-06-30 0001369568 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-06-30 0001369568 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001369568 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001369568 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001369568 us-gaap:CollaborativeArrangementMember cprx:DydoPharmaIncMember 2024-01-01 2024-06-30 0001369568 cprx:U.s.RightsForFycompaMember srt:MinimumMember us-gaap:RoyaltyAgreementTermsMember cprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember 2025-01-01 2025-06-30 0001369568 cprx:CalendarYears2022Through2025Member cprx:LicenseAndAssetPurchaseAgreementMember 2022-07-11 2022-07-11 0001369568 cprx:ProductRevenueNetMember 2024-04-01 2024-06-30 0001369568 us-gaap:MoneyMarketFundsMember 2025-06-30 0001369568 srt:MaximumMember 2025-01-01 2025-06-30 0001369568 us-gaap:SalesRevenueNetMember cprx:CustomerBMember